With Biogen Idec on the market [1], reporters are delving into the possibilities for the company and the potential fallout in the Boston biotech cluster that the company calls home. In one scenario, Cambridge, MA-based Biogen Idec and its big research operations are gobbled up whole by a Big Pharma company [2], with the region losing one of its oldest and biggest marquee names. But the biotech boosters in Beantown prefer to look on the sunny side of things, speculating about a deal that could enhance local work on biologics. Right now, biotech companies in general are fetching a premium [3] as pharma buys in to the next generation of therapies.
Biogen Idec's quarterly profit, meanwhile, slid 24 percent on a charge related to the consolidation of Cardiokine [4].
- read the report [5] from The Boston Globe
- here's a report [6] from the Wall Street Journal on Biogen Idec's numbers
Related Articles:
Biogen Idec in play after Icahn makes his move. Report [1]
Boston biotech booming as scientific research flourishes. Report [7]
The growing power of biotech. Report [8]
Biotech stocks surge as investors anticipate buyouts. Report [3]
Speculation soars over Pfizer's interest in biotech. Report [2]
Links:
[1] http://www.fiercebiotech.com/story/biogen-idec-play-after-icahn-makes-his-move/2007-10-15
[2] http://www.fiercebiotech.com/story/speculation-soars-over-pfizers-interest-biotech/2007-10-18
[3] http://www.fiercebiotech.com/story/biotech-stocks-surge-investors-anticipate-buyouts/2007-10-22
[4] http://www.fiercebiotech.com/story/biogen-inks-220m-deal-for-cardiokine-drug/2007-07-02
[5] http://www.boston.com/business/globe/articles/2007/10/23/whats_next_for_biogen_idec/
[6] http://online.wsj.com/article/SB119313990289768306.html?mod=health_home_stories
[7] http://www.fiercebioresearcher.com/story/boston-biotech-booming-as-scientific-research-flourishes/2007-05-15
[8] http://www.fiercebiotech.com/story/growing-power-biotech/2007-10-15